ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1501

Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria

Maddalena Larosa1, Nathalie Morel2, Meriem Belhocine3, Amelia Ruffatti4, Nicolas Martin Silva5, Romain Paule6, Luc Mouthon7, Michel Dreyfus8, Jean-Charles Piette9, Odile Souchaud-Debouverie10, Catherine Deneux-Tharaux11, Vassilis Tsatsaris12, Emmanuelle Pannier Metzger13, Gaëlle Guettrot-Imbert14, Veronique Le Guern15, Andrea Doria16 and Nathalie Costedoat-Chalumeau17, 1Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, 2AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, 3Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, 4Department of Medicine, University of Padova, Padova, Veneto, Italy, 5Centre Hospitalier et Universitaire de Caen, Caen, France, 6Foch Hospital, Paris, France, 7Hopital Cochin - Paris University, Paris, France, 8CHU de Caen, Caen, France, 9Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, 10CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, 11INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, 12Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, 13Maternité Port-Royal,Hôpital Cochin, Paris, France, 14Médecine Interne,Hôpital Cochin, paris, France, 15Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, 16University of Padua, Padua, Italy, 17APHP, Université de Paris, Paris, France

Meeting: ACR Convergence 2020

Keywords: antiphospholipid syndrome, Autoantibody(ies), classification criteria, pregnancy, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Reproductive Issues in Rheumatic Disorders (1497–1501)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is known on this topic, our aim was to describe severe PE in a cohort of APS patients and to report the thrombotic and obstetrical outcomes in these patients.

Methods: Retrospective study of female patients referred to 5 French Internal Medicine departments and 1 Italian Rheumatology Unit with a severe PE according to standard definition1, that occurred before 34 WG between 2000 and 2018 in patients with APS2. In case of more than one episode of severe PE in one given patient, we defined the index pregnancy as the first episode. We considered that women had been treated during pregnancy if they were prescribed low-dose aspirin (LDA) and/or low-molecular-weight heparin (LMWH) before the diagnosis of severe PE.

Results: The study included 40 women with APS, with a median follow-up after the index pregnancy with PE of 3 years. 12 (30%) had an associated SLE. 33 women (82.5%) had a positive LAC and 21 women (52.5%) had triple positivity anti-phospholipid (aPL) positivity.

  • During the index pregnancy, PE occurred at a median term of 25.5 WG. 29 pregnancies (72.5%) led to a live birth but 5 severely premature neonates died (i.e. a total of 24 pregnancies resulted to a living child). Data on PE are described Table 1.
  • Thrombotic criteria: 16 women (40%) had at least one thrombotic event. Their first thrombosis occurred before (n=14) or after the index pregnancy (n=2). Thromboses were venous (n=6), arterial (n=12), and/or micro-thrombotic (n=5). Four patients experienced a catastrophic APS (CAPS), 3 of them simultaneously with PE.
  • Obstetrical criteria: when considering all their pregnancy (n=122), 17 patients (42.5%) had at least one intra-uterine fetal death (IUFD), and 19 women (47.5%) had at least one HELLP syndrome. None of the 40 patients presented 3 or more consecutive miscarriages.

Conclusion: During the 40 index pregnancies, severe PE occurred early in the pregnancy with a high rate of in utero (n=11) or neonatal (n=5) mortality of the offspring.

APS was characterized by a strong autoimmune anti-phospholipid serology and SLE was frequent (30%).

Among these 40 APS patients with severe PE, almost half also experienced at least one thrombosis, a HELLP syndrome and/or an IUFD. However, no overlap with the «three consecutive miscarriages” classification criterion was found in our cohort suggesting that the underlying physiopathology of these 2 obstetrical phenotypes are completely different. 

References:

  1. Diagnosis and Management of preeclampsia and eclampsia. International Journal of Gynecology &Obestetrics 2002;77:67-75.

  1. Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295e 306


Disclosure: M. Larosa, None; N. Morel, None; M. Belhocine, None; A. Ruffatti, None; N. Martin Silva, None; R. Paule, None; L. Mouthon, None; M. Dreyfus, None; J. Piette, None; O. Souchaud-Debouverie, None; C. Deneux-Tharaux, None; V. Tsatsaris, None; E. Pannier Metzger, None; G. Guettrot-Imbert, None; V. Le Guern, None; A. Doria, GlaxoSmithKline, 5, 8, Eli Lilly, 5, 8, Roche, 5, 8, Janssen, 5, 8, Pfizer, 5, 8; N. Costedoat-Chalumeau, None.

To cite this abstract in AMA style:

Larosa M, Morel N, Belhocine M, Ruffatti A, Martin Silva N, Paule R, Mouthon L, Dreyfus M, Piette J, Souchaud-Debouverie O, Deneux-Tharaux C, Tsatsaris V, Pannier Metzger E, Guettrot-Imbert G, Le Guern V, Doria A, Costedoat-Chalumeau N. Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/obstetrical-outcome-and-thromboses-in-a-multicentric-cohort-of-antiphospholipid-syndrome-aps-patients-with-severe-preeclampsia-an-analysis-of-aps-classification-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obstetrical-outcome-and-thromboses-in-a-multicentric-cohort-of-antiphospholipid-syndrome-aps-patients-with-severe-preeclampsia-an-analysis-of-aps-classification-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology